Data to be presented at American Society of Anesthesiologists Annual Meeting as Masimo showcases world's first-and-only noninvasive and continuous hemoglobin (SpHb) and Oxygen Content (SpOC) monitor with live booth demonstrations
IRVINE, Calif., Oct. 17 /PRNewswire-FirstCall/ -- Masimo, the inventor of
Pulse CO-Oximetry(TM) and Measure-Through-Motion-and-Low-Perfusion pulse
oximetry, announced today that five new independent and objective studies
demonstrating Masimo PVI to be highly predictive of patient fluid status will
be presented at the American Society of Anesthesiology (ASA) Annual Meeting in
Orlando, Fla., October 19-21, 2008.
Fluid administration is critical to optimizing patient status and enabling
end organ preservation, but traditional methods to guide fluid administration
are invasive and often fail to predict fluid responsiveness. PVI has been
shown to predict fluid responsiveness in mechanically ventilated patients
under general anesthesia during surgery, and may help clinicians optimize
fluid administration and improve patient outcomes.(2-4)
Also at ASA for the first time, Masimo will be showcasing live
demonstrations of the first-ever noninvasive and continuous hemoglobin (SpHb)
and Oxygen Content (SpOC) monitor. SpHb provides instantaneous hemoglobin
measurements that may facilitate faster, easier, safer, and better clinical
decisions by allowing clinicians to more quickly detect chronic or acute
anemia, identify occult bleeding earlier, and more effectively manage blood
transfusions. While oxygen saturation (SpO2) and hemoglobin are considered
critical parameters for patient management, neither parameter by itself can
indicate the actual amount of oxygen in the blood. However, now with Masimo
Rainbow SET Pulse CO-Oximetry, SpHb and SpO2 can be used together to provide
clinicians with the first-and-only technology for real-time and noninvasive
oxygen content (SpOC(TM)) monitoring, providing a more complete picture of
oxygenation status and potentially allowing earlier indication of when a
patient crosses the threshold into a critical oxygen deficit.
The following studies will be presented at the ASA Annual Meeting:
Impact of PEEP on Perfusion Index and Plethysmographic Variability
Index(1)-A1068, Presented: October 20, 2008, 2:00-4:30 p.m., Room Hall E2-Area
M
Ability of Pleth Variability Index to Non Invasively Predict the
Hemodynamic Effects of PEEP(2)-A1608, Presented: October 22, 2008,
8:00-9:30 a.m., Room 230C
Ability of Pleth Variability Index to Detect Preload Changes in Orthotopic
Liver Transplant Patients(3)-A1605, Presented: October 22, 2008,
8:00-9:30 a.m., Room 230C
Pleth Variability Index: A Noninvasive Device for Fluid Responsiveness
Assessment during Anesthesia(4)-A1604, Presented: October 22, 2008,
8:00-9:30 a.m., Room 230C
Impact of Lower Extremity Nerve Blockage on Oximeter Perfusion Index &
Pleth Variability Index(5)-A1603, Presented: October 22, 2008, 8:00-9:30 a.m.,
Room 230C
Michael O'Reilly, MD, EVP of Medical Affairs at Masimo, stated; "These
studies add to the evidence showing that PVI can provide clinicians with an
effective and efficient noninvasive method of continuously measuring their
patient's fluid volume. This should enable more accurate fluid administration
decisions -- allowing clinicians to add a level of certainty and immediacy
toward managing intravascular fluid volumes and cardiac output both inside and
outside of the operating room."
PVI is available as part of Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) --
the first-and-only technology platform to noninvasively measure blood
constituents and fluid responsiveness that previously required invasive
procedures, including: noninvasive & continuous total hemoglobin (SpHb(TM)),
oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO(R)), methemoglobin
(SpMet(R)) and Pleth Variability Index (PVI), in addition to the 'gold
standard' measure-through-motion-and-low-perfusion performance of Masimo
SET(R) Oxygen Saturation (SpO2), Pulse Rate (PR) and Perfusion Index (PI).
About Masimo
Masimo (Nasdaq: MASI) develops innovative monitoring technologies that
significantly improve patient care -- helping solve "unsolvable" problems. In
1995, the company debuted Measure-Through-Motion-and-Low-Perfusion pulse
oximetry, known as Masimo SET, which virtually eliminated false alarms and
increased pulse oximetry's ability to detect life-threatening events. More
than 100 independent and objective studies demonstrate Masimo SET provides the
most reliable SpO2 and pulse rate measurements even under the most challenging
clinical conditions, including patient motion and low peripheral perfusion.
In 2005, Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry, a
breakthrough noninvasive blood constituent monitoring platform that can
measure many blood constituents that previously required invasive procedures.
Masimo Rainbow SET continuously and noninvasively measures total hemoglobin
(SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO(R)),
methemoglobin (SpMet(R)), and PVI(TM), in addition to oxyhemoglobin (SpO2),
pulse rate (PR), and perfusion index (PI), allowing early detection and
treatment of potentially life-threatening conditions. Founded in 1989, Masimo
has the mission of "Improving Patient Outcomes and Reducing Cost of Care by
Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at
http://www.masimo.com.
Forward Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, in connection with the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are based on current
expectations about future events affecting us and are subject to risks and
uncertainties, all of which are difficult to predict and many of which are
beyond our control and could cause our actual results to differ materially and
adversely from those expressed in our forward-looking statements as a result
of various risk factors, including, but not limited to: risks related to our
belief that Masimo PVI and total hemoglobin (SpHb(TM)) will deliver a
sufficient level of clinical improvement over alternative fluid assessment and
hemoglobin measurement capabilities to allow for rapid adoption of the
technology, risks related to our assumptions regarding the repeatability of
clinical results, and risks related to our assumptions regarding timing or
commercial availability of SpHb, as well as other factors discussed in the
"Risk Factors" section of our Quarterly Report on Form 10-Q for the fiscal
quarter ended June 28, 2008, filed with the Securities and Exchange Commission
("SEC") on August 5, 2008, which may be obtained for free at the SEC's website
at http://www.sec.gov. Although we believe that the expectations reflected in
our forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included in
this press release are expressly qualified in their entirety by the foregoing
cautionary statements. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of today's date. We do not
undertake any obligation to update, amend or clarify these forward-looking
statements or the "Risk Factors" contained in our Quarterly Report on Form
10-Q for the fiscal quarter ended June 28, 2008, whether as a result of new
information, future events or otherwise, except as may be required under the
applicable securities laws.
(1) Impact of PEEP on Perfusion Index and Plethysmographic Variability
Index. Nitin K. Shah, M.D., Darin V. Allred, M.D., Laverne Estanol, M.S.,
Brian Fine, B.S., Gandhi Vipal, B.S. Anesthesiology, Long Beach VAHS, Long
Beach, California.
(2) Ability of Pleth Variability Index to Non Invasively Predict the
Hemodynamic Effects of PEEP. Olivier Desebbe, M.D., Cecile Boucau, R.D.,
Pascal Rosamel, M.D., Jean-Jacques Lehot, M.D., Ph.D., Maxime Cannesson, M.D.
Department of Anesthesiology, Louis Pradel Hospital, Lyon-Bron, France.
(3) Ability of Pleth Variability Index to Detect Preload Changes in
Orthotopic Liver Transplant Patients. Christopher Wray, M.D., Jack Buckley,
M.D., Derek Kwan, B.S., Tayeba Maktabi, Aman Mahajan, M.D., Ph.D.
Anestheiology, UCLA David Geffen School of Medicine, Los Angeles, California.
(4) Pleth Variability Index: A Noninvasive Device for Fluid Responsiveness
Assessment during Anesthesia. Olivier Desebbe, M.D., Bertrand Delannoy, R.A.,
Jean-Jacques Lehot, M.D., Ph.D., Olivier Bastien, M.D., Ph.D., Maxime
Cannesson, M.D. Department of Anesthesiology, Louis Pradel Hospital,
Lyon-Bron, France.
(5) Impact of Lower Extremity Nerve Blockage on Oximeter Perfusion Index &
Pleth Variability Index. Darin V. Allred, M.D., Nitin K. Shah, M.D., Laverne
Estanol, M.S. Anesthesiology, University of California at Irvine, Orange,
California.
Contact:
Dana Banks
Masimo Corporation
949-297-7348
Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing
Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications,
Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87, Rad-57, Rad-9,
Rad-8, Rad-5, Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or
registered trademarks of Masimo Corporation.
SOURCE Masimo